Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Carcinoma, Non-Small-Cell Lung 213Lung Neoplasms 74Neoplasms 24Adenocarcinoma of Lung 16Neoplasm Metastasis 15Mesothelioma, Malignant 15Parkinson Disease 4, Autosomal Dominant Lewy Body 12Mesothelioma 12Carcinoma 11Head and Neck Neoplasms 10Breast Neoplasms 8Adenocarcinoma, Bronchiolo-Alveolar 7Small Cell Lung Carcinoma 6Ovarian Neoplasms 6Recurrence 5Pancreatic Neoplasms 4Colorectal Neoplasms 4Adenocarcinoma 4Triple Negative Breast Neoplasms 3Stomach Neoplasms 3Squamous Cell Carcinoma of Head and Neck 3Prostatic Neoplasms 3Lung Diseases 3Laryngeal Diseases 3Carcinoma, Small Cell 3Brain Neoplasms 3Uterine Neoplasms 2Uterine Cervical Neoplasms 2Thoracic Neoplasms 2Solitary Fibrous Tumor, Pleural 2

Interventions

talimogene laherparepvec 1Surgical Procedures, Operative 1Sentinel Lymph Node Biopsy 1Pemetrexed 1Paclitaxel 1Mastectomy, Subcutaneous 1Mammaplasty 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Carcinoma, Ductal × Pemetrexed × Clear all
NCT00106002 2009-06-01

Pemetrexed as the First Treatment in Advanced or Metastatic Breast Cancer

Eli Lilly and Company

Phase 2 Completed
37 enrolled 9 charts
Breast

Breast Neoplasms, Breast Neoplasms, Male, Carcinoma, Ductal

Data powered by HemOnc (CC BY 4.0) Colophon âš¡